Skip to main content

NCI Funding for HIV and AIDS Malignancies Research

Current NCI Funding Opportunities in HIV/AIDS and AIDS Malignancies are listed below.

 

Notice of Special Interest (NOSI): Use of Biological "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers

The purpose of this Notice of Special Interest (NOSI) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. Research efforts that identify specific contributions of HIV infection and its potential interaction with other pathogens towards the development and pathogenesis of these cancers and provide information on the clinical outcomes of such cancers in the HIV-infected population are sought. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

High or medium priority AIDS research as described in NOT-OD-15-137 is encouraged in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV)

The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the modes of transmission of KSHV; the biology of the initial steps of infection; and the risk factors of infection. The proposed studies should inform and advance efforts to reduce or eliminate KSHV transmission and prevention of  Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of HIV infection.

Additional Information:
Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus 
(KSHV) (R01 Clinical Trial Optional)

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions

The goal of this Funding Opportunity Announcement (FOA) is to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity and build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs including cancer in persons living with HIV (PLWH). 

Additional Information:
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country 
Institutions (R21 Clinical Trial Optional)

Multidisciplinary Studies of HIV/AIDS and Aging

This initiative solicits applications at the intersection of HIV and aging.  NCI is interested in studies that help to understand how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer.

Additional Information:
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

Harnessing Big Data to Halt HIV

This funding opportunity announcement (FOA) encourages applications that will transform understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). NIH is interested in promoting and applying Big Data Science technologies, computing, informatics, and analytics to address gaps in our understanding of HIV transmission risks, social networks, and the HIV treatment continuum including comorbidities such as cancer.

Additional Information:
Harnessing Big Data to Halt HIV (R01)

Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle Income Countries

NCI is interested in encouraging applications that propose evidence based studies to reduce cancer stigma among healthcare providers, caregivers and cancer patients living with HIV/AIDS.

Additional Information:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care in Low and Middle-
Income Countries (R21 Clinical Trial Optional)
  • Updated: